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LETTERS TO THE EDITOR	
Digoxin Withdrawal in Patients With
Head Failure
The report by Uretsky et al
. (t) is the second of two recent
withdrawal studies
(i,2)
that claim to show some advantage from the
use
of digoxin in the treatment of patients
with heart failure . The two
studies add to the large number of earlier studies that have used the
withdrawal design (3) .
The authors are parsimonious in enumerating
the limitations of their study .
A
withdrawal study addresses
the question whether stopping
the use of a drug brings about a change in the clinical condition of
the patient, not whether the drug should
have been prescribed in the
first place, Patients are selected
from those known to tolerate the
drug
. Such a subset of patients with heart failure may have unique
characteristics.
The major clinical question is not whether digoxin has a positive
isotropic effect or brings about clinical
benefit to selected patients
with heart failure but whether
the addition of digoxin to optimal
treatment with a diuretic agent and angiotensin-converting enzyme
inhibitor confers any
additional advantage to the patient . If a
withdrawal study is undertaken
to test this hypothesis, then on
withdrawal of the drug those patients randomized to placebo should
have their therapy manipulated either by an increase in the diuretic
agent, the addition of a
combination of diuretic agents or an
alteration in the dose of the angiotensin-converting enzyme inhibi-
tor. The two recent studies are at best tests
of the efficacy of digoxin
(not in dispute under particular circumstances) but are decidedly not
a fair test of a therapeutic strategy .
The most serious criticism of withdrawal
studies is that interpre-
tation of the results is ambiguous .
If, as was observed in this study,
there is deterioration in the placebo group on withdrawal of the
investi tional drug, a possible conclusion would be that the drug
has conferred benefit . An alternative conclusion is that the drug was
sufficiently efficacious to conceal any clinical deterioration while the
drug was being administered but at the same time caused harm .
Isotropic drugs can hasten cell death in the presence of myocardial
ischemia or in metabolically challenged myocytes . Under such
circumstances, cessation of the drug will be followed by deteriora-
tion of the patient. The deterioration is a measure of the harm
caused by the drug . Thus, the same outcome
can be used to argue
for efficacy or harm . Withdrawal studies are quite correctly not used
to investigate new drugs in heart failure .
The debate on the ~ linical use of digoxin will continue for many
years. The key issue is whether
a potentially harmful drug adds
benefit to established conventional treatment and whether there are
subgroups of patients in whom there is a particular benefit or harm
.
The outcome of the current mortality
study conducted by the
National Institu es of Health may provide
more convincing evidence
for the use of digoxin, namely, to influence long-term mortality
rather than to ameliorate symptoms.
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Reply
Dr. Paole-Wilson has several concerns about the recently published
placebo-controlled digoxin trial (PROVED) (1). He questions the
scientific validity of a drug withdrawal design . Such a design was
necessitated by the nearly universal use of digoxin in the treatment
of heart failure in this country at the time that this study was
promulgated
. A limitation of this design, not mentioned by Dr .
Poole-Wilson, is more on the ethical level, that is, clinical worsening
in the group withdrawn from the active therapeutic agent . To
safeguard against "excessive" deterioration,
the protocol mandated
that study coordinators contact patients weekly by telephone to
assess clinical status . If in a controlled trial, all measured baseline
variables are not significantly different and the only difference
during active phase is drug (digoxin) withdrawal in one patient
group, then it is completely reasonable to conclude that a worsening
in the placebo-treated group is due to withdrawal of the active agent
(digoxin) 6c ., digoxin has clinical efficacy)
. On the basis of the
PROVED study . it
is an extrapolation
to conclude that beginning
digoxin therapy in patients with clinical heart failure improves their
clinical status
. but it is more a "small step" than a "leap" of faith .
Dr
. Poole-Wilson questions whether digoxin can improve clinical
status in patients taking an angiotensin-converting enzyme inhibitor
and diuretic agents . The RADIANCE trial, with identical method-
ology to PROVED, except that patients were taking an angiotensin-
converting enzyme inhibitor by design, showed nearly identical
results to the PROVED trial (2) .
Whether, in addition to an angiotensin-converting enzyme inhib-
itor, using digoxin or increasing the dose of a diuretic agent, as Dr .
Poole-Wilson suggests, is a more appropriate strategy in the treat-
ment of decompensated heart failure, we would leave to the treating
physician, We would remind Dr. Poole-Wilson of the negative
effects of diuretic agents, particularly hypokalemia and hypontag-
nesemia, which may increase the propensity to fatal arrhythmias
and also further activation of potentially harmful neurohormonal
axes
.
Dr. Poole-Wilson states that the PROVED trial cannot answer
whether digoxin "should have been prescribed in the first place ."
We would remind Dr. Poole-Wilson that digoxin was prescribed in
all patients for at least one episode of clinical heart failure secondary
to systolic dysfunction . We would venture to say that tolerance to
oral digoxinn is high and that this
"subset" probably represents the
vast majority of patients with systolic dysfunction and clinical
congestive heart failure .
Finally, Dr
. Poole-Wilson muddies the issue of clinical efficacy of a
drug and its effect on survival. The PROVED (and RADIANCE) trials
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(1 .2) . as well as several previously reported prospective drug "add-on"
trials (3-6) . provide very strong evidence of digoxin's clinical efficacy .
The issue of digoixin's e&ct on survival must, as we pointed out in our
article, be addressed (its is currently underway) to complete the drug's
clinical profile,
BARRY F. URETSKY, MD
JAMES B . YOUNG. MD
M. K. JOLLY. PHAPNiD
Catheterization Laboralon
D424
	
ulfiirersitv Himpital
Pittsburgh . Pennsylvania 152I.
References
1 . Uret"y 111' . Young JR . Slialudi FF, Vellen LG, Harrison NIC, Jolly MK . Randomized
study assessing the ctlect of digoxin withdrawal in patients with mild to modest
chronic congestive heart failure : results of the PROVED tmil . I Am roll Cardiol
093MANW .
1 Parker W Wmqhdc W Young J& a ,d . Randomized . AwMablioul, placeK
controlled. withdrawal sandy of digoxin in patients wah chronic heart failure treated
with ,;onverting-enzyme inhibitors . N Engl J ht td 1953,329 .) •7
3 . Captopril Mullicenici Re%uarch Group. C01111%1141isC effect of flldupy V01111 CapWpril
and 4mm w pwin %ith mild so moderate heart i*ailwe JANIA 11)814,219 :511)-44
GqA 04 Wan MA. Felon EL. 0 a A controlled ii J of digosm in congestive
heart fitifure. Am J Caidiul
5 . Diffiance K . Shabetai R, Kosiuk W . Moran J, SNant RC . Wright R. fur the Milrinoii
MulliventerTrial Group Ural milruione and digomn in lican failure : rOUILSON Placcho
controlled prospective trial of tacit agent dtid the cunibimilion, N EN J pied
1981020 :677-83
6 . German and Aumnan Xantorcroll Study Group . Rouble-blind plactbu-cuntrolled com-
parison of digoxin and xamoicrol in chronic heart failure
. Lancet 1989 :1 :488-92 .
Synchronized Coronary Venous Retroperfusion
We would like to comment on the recently published report by
Boekstegers et al . (1) . We as scientists who have used the technique
of synchronized coronary venous retroperfusion extensively, both
experimentally and clinically, would like to caution the readers with
regard to certain issues before they extrapolate these data clinically .
Our concerns regard safety, feasibility and efficacy .
With respect to safety, it has been - ;town in several studies (2-4)
that retroperfusion coronary venous pressures <40 mm Hg (mean
pressure) and 60 mm Hg (peak pressure) were safe
. The manufac-
turer also limits mean pressures at 40 min Hg (5) . In this study
during retroperfusionlretroi nfus ion, the coronary venous pressures
were as high as 89 ± 24 mm Hg for peak pressure and 61 ±
16 mm Hg for mean pressure (I [Table 31) . In a previous publication,
Boekstegers et al . (6) state that pressures >50 mm Hg are dangerous
and lead to myocardial hemorrhage and edema . The authors did not
observe any detrimental effects from these high pressures ; however,
the duration of pumping support retruperfusion in these studies was
limited to 10 min . On the basis of previous clinical studies, and to
ensure safely of the synchronized retroperfusion technique, the
pump is actually equipped with a cutoff switch that shuts off the
pump when unacceptably high pressures develop within the coro-
nary veins (5) . Also of note is that the rest pressures in the animal
before the start of retroperfusion were high at -20 mm Hg,
indicating probable venous occlusion by the balloon-tipped 8 .5F
synchronized retroperfusion catheter, thus hampering venous drain-
age. Previous safety studies (2-4) demonstrate the importance of
normal rest coronary venous pressure, which must equal right atrial
pressure to ensure adequate venous drainage .
The feasibility of the synchronized retroperfusion technique
encompassed the rapidity with which the technique can be set dp
and the catheter insertion time . Retroperfusion has been effective
when the catheter is placed in the great cardiac vein . Selective
cannulation of the anterior interventricular vein is not necessary .
The authors suggest greater efficacy if the anterior interventricular
vein is cannulated, which will make the technique more time-
consuming and protection restricted to left anterior descending
coronary artery territory . Retroperfusion is dependent or, arterio-
venous gradients ; hence the retroperfusate will go toward the
ischemic areas (low pressure) even without selective cannulation of
the draining veins (7) .
Boekstegers et al . (1) used intra myocardial oxygen tension and
regional myocardial function using ultrasound crystals as end
points
. The efficacy with suction and retroinfusion did reach statis-
tical significance . but we are unsure whether the degree of improve-
ment is clinically relevant . The authors used a 10-min ischemia
followed by a 50-min reperfusion model . This does not simulate a
percutaneous Iransluminal coronary angioplasty model adequately,
where there are repeated episodes of short ischemia . The 50-min
reperfusion eficr 10-min occlusion was too short to cause myocar-
dial necrosis or simulate an acute myocardial infarction . The study
thus has limited clinical applicability .
The technique of synchronized coronary venous retroperfusion
when applied property and according to the instructions of the
manufacturer (Relroperfusion Systems, Inc . !5)) has been shown to
be safe, feasible and effective in numerous clinical trials (8-11 . Me
manufacturer has recently been issued a letter of approval from the
U .S. Food and Drug Administration on the basis of the safely
guidelines and effectiveness of the technique
. As scientists involved
in the original experimental and clinical studies, we have great
concern with regard to applicability of this technique by Boekste-
gers et al
. (I) .
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